## **Result Update**

# **Hero Motocorp**



Your success is our success

Refer to important disclosures at the end of this report

Weak quarter; Domestic 2W recovery on track

**CMP** Rs 2,410 as of (May 4, 2022)

**Target Price** Rs 2,940 (A)

Rating **BUY** (**■**) **Upside** 22.0 %

FY24E

- Q4FY22 EBITDA declined by 32% yoy to Rs8.3bn, 14% below estimates, affected by higher other expenses due to the bunching up of CSR expenses and Vida brand launch costs. Revenue fell 15% to Rs74.2bn, in line with estimates.
- We expect a 12% volume CAGR in the domestic market over FY22-24E, supported by a pickup in rural demand and the opening of educational institutions/offices. In addition, exports are expected to see a 17% CAGR, owing to improved penetration in the Africa and Latin America regions.
- HMCL will aggressively focus on the EV space through own products (first launch by Jul'22), a joint development with Gogoro for a swappable battery model (launch by end of FY23) and investments in Ather Energy. It has set up an E-2W and battery assembly facility at its Andhra Pradesh plant.
- Stock catalysts include a rebound in 2W demand and incremental announcements on the EV business. Retain Buy with a TP of Rs2,940 (Rs2,850 earlier), based on 15x core Jun'24E EPS (Mar'23E EPS earlier), net cash of Rs437/share and the value of investments at Rs119/share.
- EBITDA below estimates: Revenue declined by 15% yoy to Rs74.2bn, broadly in line with our estimate of Rs74.5bn. Volume fell 24%, while realization grew by 13%. The gross margin expanded by 110bps to 30.7%. Even on a sequential basis, the margin has improved due to price hikes. The EBITDA margin contracted by 280bps to 11.2%. EBITDA declined by 32% to Rs8.3bn, 14% lower than estimates, owing to higher other expenses (+13%). Other expenses/revenue rose 310bps to 13.1%, higher by 80-90bps due to the bunching up of CSR spends (50-60bps) and Vida brand launch expenses (30-40bps). Other income grew by 60% to Rs1.4bn. The effective tax rate was lower at 22% vs. 25% in Q3FY22 and 24% in Q4FY21. Overall, the adjusted PAT declined 28% to Rs6.3bn (est.: Rs6.8bn). The earnings fall is lower than the EBITDA fall due to higher other income and a lower tax rate. The share of losses from associates stands at Rs203mn vs. a profit of Rs198mn in Q3FY22 and Rs378mn in Q4FY21.
- Retain Buy with a TP of Rs2,940. We build in revenue/earnings CAGRs of 16%/21% over FY22-24E, with healthy FCF generation (~Rs26bn/year or 5% yield). We also introduce FY25E EPS at Rs199.3, factoring in volume growth of 7% and EBITDA margin of 12.9%. Key downside risks are lower-than-expected demand in key geographies, increase in competitive intensity, failure of new products, further increase in commodity prices and adverse currency rates.

Please see our sector model portfolio (Emkay Alpha Portfolio): Automobiles & Auto Ancillaries (Page 9)

#### Financial Snapshot (Standalone)

(Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Revenue	308,006	292,455	336,786	392,016	429,184
EBITDA	40,192	33,688	38,776	49,703	55,329
EBITDA Margin (%)	13.0	11.5	11.5	12.7	12.9
APAT	29,642	24,730	28,244	36,055	39,815
EPS (Rs)	148.4	123.8	141.4	180.5	199.3
EPS (% chg)	(6.9)	(16.6)	14.2	27.7	10.4
ROE (%)	20.2	16.0	17.4	21.0	21.7
P/E (x)	16.2	19.5	17.0	13.4	12.1
EV/EBITDA (x)	9.9	11.9	10.2	7.8	6.9
P/BV (x)	3.2	3.1	2.9	2.7	2.5

Change in Estimates	
EPS Chg FY23E/FY24E (%)	0.8/(0.8)
Target Price change (%)	3.2
Target Period (Months)	12
Previous Reco	BUY
Emkay vs Consensus	

FY23E

# **EPS Estimates**

Emkay	141.4	180.5
Consensus	163.0	194.2
Mean Consensus TP (12I	M)	Rs 2,937
Stock Details		
Bloomberg Code		HMCL IN
Face Value (Rs)		2
Shares outstanding (mn)		200
52 Week H/L	3,0	79 / 2,147
M Cap (Rs bn/USD bn)	4	481 / 6.30
Daily Avg Volume (nos.)		939,921
Daily Avg Turnover (US\$	mn)	29.9

Shareholding Pattern Mar '22	
Promoters	34.8%
Fils	29.2%
DIIs	24.2%
Public and Others	11.8%

Price Performance										
(%)	1M	3M	6M	12M						
Absolute	4	(11)	(10)	(13)						
Rel. to Nifty	10	(7)	(4)	(24)						

#### Relative price chart



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

#### Raghunandhan N L

raghunandhan.nl@emkayglobal.com +91 22 6624 2428

#### Mumuksh Mandlesha

mumuksh.mandlesha@emkayglobal.com +91 22 6612 1334


#### Bhargava Perni

bhargava.perni@emkayglobal.com

รงุนกระเ<mark>ออาการ โลแะลมเอียรายาก</mark>eam.emkay@whitemarquesolutions.com use and downloaded at 05/05/2ช่**91** 23<u>66</u>34 2429


# Story in Charts

Exhibit 1: Q4FY22 volume stood at 1.2mn units; Volume expected to grow by 13% CAGR over FY22-24E




Source: Company, Emkay Research

Exhibit 3: Revenue/unit grew by 13% yoy to Rs62,426, led by price hikes and better mix




Source: Company, Emkay Research

Exhibit 5: EBITDA margin contracted by 280bps to 11.2%, due to lower scale and higher other expenses; Expect margin to expand to 12.7% by FY24E




Source: Company, Emkay Research

Exhibit 2: Domestic 2W market share stood at 33%




Source: SIAM, Emkay Research

Exhibit 4: Gross margin grew by 110bps to 31%, due to price hikes and cost reduction efforts



Source: Company, Emkay Research

Exhibit 6: One-year forward P/E (Average: 18x, +1sd: 21x, -1std: 16x)



Source: Company, Emkay Research

# **Earnings Call Highlights**

#### **Outlook**

- Domestic volumes will grow in double digits in FY23. The company is witnessing strong festive/marriage season demand in Q1FY23. The pickup in rural demand and the reopening of colleges/offices should support volumes ahead.
- Expects the ICE industry's growth to continue over the next few years, despite increasing penetration of EVs.
- Multiple launches are lined up in scooters and premium motorcycles in FY23. A major launch is an electric scooter under the Vida brand to be launched in Jul'22. Also, Hero-Gogoro swappable battery scooter will be launched in FY23.
- Exports saw robust growth of 57% in FY22, and the company expects upward momentum to continue in FY23. There is now a strong focus on further expanding its presence in markets such as Colombia, Peru, Argentina and Mexico in Latin America; Kenya, Uganda and Tanzania in East Africa; Nigeria in West Africa; and Bangladesh and Nepal in Asia.
- Commodity inflation hit is expected in Q1FY23. To partially offset the impact, the company has implemented a price hike of ~1.5%.
- Investments of Rs2.7bn are expected in Q1FY23. The total investments will increase to Rs9.3bn.

# Q4FY22 highlights

- Dealer inventory stood at 7-8 weeks as of Mar'22. It has currently declined to 6-7 weeks, owing to strong marriage/festive season demand. A comfortable position for dealer inventory is ~6 weeks.
- The gross margin expansion was driven by price hikes, which were higher than commodity inflation. There is no deferral in price hikes to vendors.
- Other expenses were higher due to the bunching up of CSR spends (50-60bps) and Vida launch expenses (30-40bps).
- Spares revenue grew by 10% to Rs11.5bn.
- The financing ratio stood at 54%. Of this, Hero Fincorp contributed 34%.

Exhibit 7: Volume assumptions: Expect revenue CAGR of 16% over FY22-24E

Volume (units)	FY19	FY20	FY21	FY22	FY23E	FY24E	FY25E	FY22-24E CAGR (%)
Domestic Motorcycles	6,893,688	5,828,782	5,156,401	4,337,634	4,751,823	5,425,862	5,807,451	12
Growth (%)	6.1	(15.4)	(11.5)	(15.9)	9.5	14.2	7.0	
Export Motorcycles	187,185	161,567	171,963	290,131	362,664	398,930	430,845	17
Growth (%)	5.1	(13.7)	6.4	68.7	25.0	10.0	8.0	
Domestic Scooters	719,087	402,676	443,458	305,892	357,894	400,841	424,891	14
Growth (%)	(18.6)	(44.0)	10.1	(31.0)	17.0	12.0	6.0	
Export Scooters	20,871	16,694	14,552	10,491	31,473	34,620	37,390	82
Growth (%)	(20.7)	(20.0)	(12.8)	(27.9)	200.0	10.0	8.0	
Total Volume	7,820,831	6,409,719	5,786,374	4,944,148	5,503,853	6,260,253	6,700,577	13
Growth (%)	3.1	(18.0)	(9.7)	(14.6)	11.3	13.7	7.0	
Realization/unit (Rs)	43,027	44,988	53,230	59,152	61,191	62,620	64,052	3
Growth (%)	1.3	4.6	18.3	11.1	3.4	2.3	2.3	
Revenue (Rs mn)	336,505	288,361	308,006	292,455	336,786	392,016	429,184	16
Growth (%)	4.4	(14.3)	6.8	(5.0)	15.2	16.4	9.5	

Source: Company, Emkay Research

# **Exhibit 8: Changes in Estimates**

Rs mn	s mn FY23E					FY24E				FY25E	
	Earlier	Revised	% Change	% YoY	Earlier	Revised	% Change	% YoY	Introducing	% YoY	
Volumes	5,470,142	5,503,853	0.6	11.3	6,301,342	6,260,253	(0.7)	13.7	6,700,577	7.0	
Net Sales	334,398	336,786	0.7	15.2	393,199	392,016	(0.3)	16.4	429,184	9.5	
EBITDA	38,516	38,776	0.7	15.1	50,011	49,703	(0.6)	28.2	55,329	11.3	
Margin (%)	11.5	11.5	(0) bps	(1) bps	12.7	12.7	(4) bps	117 bps	12.9	21 bps	
APAT	28,024	28,244	8.0	14.2	36,356	36,055	(8.0)	27.7	39,815	10.4	
EPS (Rs)	140.3	141.4	0.8	14.2	182.0	180.5	(0.8)	27.7	199.3	10.4	

Source: Company, Emkay Research

#### **Exhibit 9: SOTP**

	Basis of Valuation	Equity value	Equity value/share
Core business	Core P/E of 15x Jun24E	476,426	2,385
Hero FinCorp	P/B 1x FY21 (Holdco discount of 20%)	16,370	82
Ather Energy	Investment value (Holdco discount of 20%)	7,397	37
Cash per share	As of Jun'23E		437
Total			2,940

Source: Company, Emkay Research

Exhibit 10: Actual vs. Estimates (Q4FY22)

(Rs mn)	Actual	Esti	imates	% Va	riation	Comment
(KS IIIII)	Actual	Emkay	Consensus	Emkay	Consensus	Confinent
Total Revenue	74,217	74,524	74,902	(0.4)	(0.9)	Broadly in-line with estimates
EBITDA	8,276	9,640	8,917	(14.2)	(7.2)	Below estimates due to higher other expenses
EBITDA Margin (%)	11.2	12.9	11.9	(178) bps	(75) bps	
Adjusted net profit	6,271	6,840	6,249	(8.3)	0.3	Below estimates due to lower operating profit

Source: Bloomberg, Company, Emkay Research

**Exhibit 11: Quarterly financial summary** 

Rs mn	Q4FY21	Q1FY22	Q2FY22	Q3FY22	Q4FY22	YoY (%)	QoQ (%)	FY22	FY21	YoY(%)
Revenue	86,860	54,871	84,534	78,833	74,217	(14.6)	(5.9)	292,455	308,006	(5.0)
Expenditure	74,748	49,722	73,870	69,233	65,942	(11.8)	(4.8)	258,767	267,814	(3.4)
as % of sales	86.1	90.6	87.4	87.8	88.8			354.7	268.2	
Consumption of RM	61,173	39,796	61,104	55,943	51,424	(15.9)	(8.1)	208,267	217,623	(4.3)
as % of sales	70.4	72.5	72.3	71.0	69.3			285.1	212.1	
Employee Cost	4,884	4,357	5,054	5,180	4,763	(2.5)	(8.0)	19,354	18,987	1.9
as % of sales	5.6	7.9	6.0	6.6	6.4			26.9	23.6	
Other expenditure	8,691	5,570	7,712	8,109	9,754	12.2	20.3	31,145	31,203	(0.2)
as % of sales	10.0	10.2	9.1	10.3	13.1			42.7	32.5	
EBITDA	12,112	5,148	10,664	9,600	8,276	(31.7)	(13.8)	33,688	40,192	(16.2)
Depreciation	1,631	1,630	1,639	1,644	1,585	(2.9)	(3.6)	6,498	6,769	(4.0)
EBIT	10,480	3,519	9,025	7,956	6,691	(36.2)	(15.9)	27,190	33,424	(18.6)
Other Income	874	1,386	1,569	1,216	1,398	59.9	14.9	5,569	5,799	(4.0)
Interest	63	61	65	65	67	5.9	2.3	258	218	18.1
PBT	11,291	4,844	10,529	9,107	8,022	(29.0)	(11.9)	32,501	39,004	(16.7)
Total Tax	2,642	1,189	2,585	2,246	1,752	(33.7)	(22.0)	7,771	9,362	(17.0)
Adjusted PAT	8,650	3,654	7,944	6,861	6,271	(27.5)	(8.6)	24,730	29,642	(16.6)
Extra ordinary items Loss/(Gain)	0	0	0	0	0			0	0	
Reported PAT	8,650	3,654	7,944	6,861	6,271	(27.5)	(8.6)	24,730	29,642	(16.6)
Adjusted EPS (Rs)	43.3	18.3	39.8	34.4	31.4	(27.5)	(8.6)	123.8	148.4	(16.6)
Margins (%)						(bps)	(bps)			(bps)
EBIDTA	13.9	9.4	12.6	12.2	11.2	(279)	(103)	11.5	13.0	(153)
EBIT	12.1	6.4	10.7	10.1	9.0	(305)	(108)	9.3	10.9	(155)

Source: Company, Emkay Research

13.0

10.0

23.4

8.8

6.7

24.6

12.5

9.4

24.5

11.6

8.7

24.7

10.8

8.4

21.8

(219)

(151)

(156)

(74)

(25)

(282)

11.1

8.5

23.9

12.7

9.6

24.0

(155)

(117)

(9)

EBT

PAT

Effective Tax rate

# **Key Financials (Standalone)**

### **Income Statement**

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Revenue	308,006	292,455	336,786	392,016	429,184
Expenditure	267,814	258,767	298,010	342,313	373,855
EBITDA	40,192	33,688	38,776	49,703	55,329
Depreciation	6,769	6,498	7,277	8,164	9,145
EBIT	33,424	27,190	31,499	41,538	46,185
Other Income	5,799	5,569	5,974	6,274	6,649
Interest expenses	218	258	310	372	446
PBT	39,004	32,501	37,163	47,441	52,388
Tax	9,362	7,771	8,919	11,386	12,573
Extraordinary Items	0	0	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	29,642	24,730	28,244	36,055	39,815
Adjusted PAT	29,642	24,730	28,244	36,055	39,815

# **Balance Sheet**

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Equity share capital	400	400	400	400	400
Reserves & surplus	151,585	157,430	165,903	176,719	188,664
Net worth	151,984	157,829	166,302	177,119	189,063
Minority Interest	0	0	0	0	0
Loan Funds	0	0	0	0	0
Net deferred tax liability	4,041	3,833	4,019	4,256	4,518
Total Liabilities	156,025	161,662	170,321	181,375	193,581
Net block	59,884	58,065	63,369	66,805	69,660
Investment	104,997	106,523	111,523	118,523	126,523
Current Assets	52,364	47,970	57,158	65,679	72,684
Cash & bank balance	2,572	1,751	2,798	2,405	3,410
Other Current Assets	5,849	6,525	7,514	8,746	9,575
<b>Current liabilities &amp; Provision</b>	65,585	55,478	63,729	72,033	77,686
Net current assets	(13,222)	(7,508)	(6,571)	(6,353)	(5,002)
Misc. exp	0	0	0	0	0
Total Assets	156,025	161,662	170,321	181,375	193,581

### **Cash Flow**

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
PBT (Ex-Other income) (NI+Dep)	33,205	26,932	31,189	41,167	45,739
Other Non-Cash items	0	0	0	0	0
Chg in working cap	10,700	(6,825)	(217)	(1,014)	(514)
Operating Cashflow	35,929	14,634	35,337	38,749	46,690
Capital expenditure	(5,101)	(5,240)	(10,000)	(12,000)	(12,000)
Free Cash Flow	30,828	9,393	25,337	26,749	34,690
Investments	(18,287)	1,713	(5,000)	(7,000)	(8,000)
Other Investing Cash Flow	1,288	2,008	(5,974)	(6,274)	(6,649)
Investing Cashflow	(16,301)	4,050	(15,000)	(19,000)	(20,000)
Equity Capital Raised	78	50	0	0	0
Loans Taken / (Repaid)	0	0	0	0	0
Dividend paid (incl tax)	(18,978)	(18,981)	(18,981)	(19,771)	(25,238)
Other Financing Cash Flow	(357)	(315)	0	0	0
Financing Cashflow	(19,475)	(19,504)	(19,291)	(20,142)	(25,684)
Net chg in cash	153	(820)	1,047	(393)	1,005
Opening cash position	2,419	2,572	1,751	2,798	2,405
Closing cash position	2,571	1,751	2,798	2,405	3,410

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 05/05/2022 03:49 PM

K	ev	Da	.+i	^
n	ev	Πč	1LI	OS

Profitability (%)	FY21	FY22	FY23E	FY24E	FY25E
EBITDA Margin	13.0	11.5	11.5	12.7	12.9
EBIT Margin	10.9	9.3	9.4	10.6	10.8
Effective Tax Rate	24.0	23.9	24.0	24.0	24.0
Net Margin	9.6	8.5	8.4	9.2	9.3
ROCE (post-tax)	16.6	12.9	14.2	17.7	18.5
ROE	20.2	16.0	17.4	21.0	21.7
RoIC (post-tax)	46.0	40.1	43.2	53.6	55.9

Per Share Data (Rs)	FY21	FY22	FY23E	FY24E	FY25E
EPS	148.4	123.8	141.4	180.5	199.3
CEPS	182.2	156.3	177.8	221.3	245.0
BVPS	760.7	789.9	832.3	886.5	946.3
DPS	105.0	95.0	99.0	126.3	139.5

Valuations (x)	FY21	FY22	FY23E	FY24E	FY25E
PER	16.2	19.5	17.0	13.4	12.1
P/CEPS	13.6	15.9	14.0	11.2	10.2
P/BV	3.2	3.1	2.9	2.7	2.5
EV / Sales	1.3	1.4	1.2	1.0	0.9
EV / EBITDA	9.9	11.9	10.2	7.8	6.9
Dividend Yield (%)	4.4	3.9	4.1	5.2	5.8

Gearing Ratio (x)	FY21	FY22	FY23E	FY24E	FY25E
Net Debt/ Equity	(0.6)	(0.5)	(0.5)	(0.5)	(0.5)
Net Debt/EBIDTA	(2.1)	(2.4)	(2.2)	(1.9)	(1.8)
Working Cap Cycle (days)	(18.7)	(11.6)	(10.2)	(8.2)	(7.2)

Growth (%)	FY21	FY22	FY23E	FY24E	FY25E
Revenue	6.8	(5.0)	15.2	16.4	9.5
EBITDA	1.5	(16.2)	15.1	28.2	11.3
EBIT	6.4	(18.6)	15.8	31.9	11.2
PAT	(18.4)	(16.6)	14.2	27.7	10.4

Quarterly (Rs mn)	Q4FY21	Q1FY22	Q2FY22	Q3FY22	Q4FY22
Revenue	86,860	54,871	84,534	78,833	74,217
EBITDA	12,112	5,148	10,664	9,600	8,276
EBITDA Margin (%)	13.9	9.4	12.6	12.2	11.2
PAT	8,650	3,654	7,944	6,861	6,271
EPS (Rs)	43.3	18.3	39.8	34.3	31.4

Source: Company, Emkay Research


Shareholding Pattern (%)	Mar-21	Jun-21	Sep-21	Dec-21	Mar-22
Promoters	34.8	34.8	34.8	34.8	34.8
FIIs	37.2	35.0	32.3	29.6	29.2
DIIs	18.7	20.2	22.0	23.7	24.2
Public and Others	9.4	10.0	11.0	12.0	11.8

Source: Capitaline

### RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
6-Apr-22	2,347	2,850	12m	Buy	Raghunandhan NL
24-Feb-22	2,490	3,700	12m	Buy	Raghunandhan NL
11-Feb-22	2,719	3,700	12m	Buy	Raghunandhan NL
13-Nov-21	2,683	3,700	12m	Buy	Raghunandhan NL
2-Jul-21	2,920	3,870	12m	Buy	Raghunandhan NL
18-Jun-21	2,891	3,870	12m	Buy	Raghunandhan NL
1-Jun-21	2,977	3,870	12m	Buy	Raghunandhan NL
30-May-21	2,992	3,870	12m	Buy	Raghunandhan NL
7-May-21	2,861	3,870	12m	Buy	Raghunandhan NL
5-Feb-21	3,429	4,000	12m	Buy	Raghunandhan NL
30-Oct-20	2,800	3,839	12m	Buy	Raghunandhan NL
11-Oct-20	3,327	3,701	12m	Buy	Raghunandhan NL
28-Sep-20	3,089	3,701	12m	Buy	Raghunandhan NL
15-Sep-20	3,037	3,701	12m	Buy	Raghunandhan NL
28-Aug-20	3,059	2,798	12m	Hold	Raghunandhan NL
15-Aug-20	2,804	2,798	12m	Hold	Raghunandhan NL
29-Jun-20	2,504	2,530	12m	Hold	Raghunandhan NL
10-Jun-20	2,292	2,530	12m	Hold	Raghunandhan NL
4-May-20	2,001	2,313	12m	Hold	Raghunandhan NL
13-Apr-20	1,919	2,313	12m	Hold	Raghunandhan NL
27-Feb-20	2,110	2,670	12m	Hold	Raghunandhan NL
20-Feb-20	2,240	2,670	12m	Hold	Raghunandhan NL
7-Feb-20	2,443	2,800	12m	Hold	Raghunandhan NL
30-Jan-20	2,482	3,150	12m	Hold	Raghunandhan NL
27-Dec-19	2,442	3,150	12m	Hold	Raghunandhan NL
27-Nov-19	2,523	3,150	12m	Hold	Raghunandhan NL
1-Nov-19	2,707	3,150	12m	Hold	Raghunandhan NL
30-Oct-19	2,685	3,150	12m	Hold	Raghunandhan NL
23-Oct-19	2,713	3,150	12m	Hold	Raghunandhan NL
1-Oct-19	2,688	3,200	12m	Hold	Raghunandhan NL
26-Sep-19	2,760	3,200	12m	Hold	Raghunandhan NL
23-Sep-19	2,820	3,200	12m	Hold	Raghunandhan NL
3-Sep-19	2,557	2,380	12m	Hold	Raghunandhan NL
28-Aug-19	2,569	2,380	12m	Hold	Raghunandhan NL
31-Jul-19	2,356	2,380	12m	Hold	Raghunandhan NL
1-Jul-19	2,617	2,585	12m	Hold	Raghunandhan NL
27-Jun-19	2,598	2,585	12m	Hold	Raghunandhan NL
3-Jun-19	2,840	2,585	12m	Hold	Raghunandhan NL
29-May-19	2,726	2,585	12m	Hold	Raghunandhan NL

# RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

Source: Company, Emkay Research

# Emkay Alpha Portfolio – Automobiles & Auto Ancillaries





Analyst: Raghunandhan NL

#### **Contact Details**

raghunandhan.nl@emkayglobal.com +91 22 6624 2428

#### Sector

Automobiles and Ancillaries

## Analyst bio

Raghu holds an MBA and comes with total 13 years of research experience. His team currently covers 17 stocks in the Indian Automobiles and Ancillaries space.

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight based on Current NAV	I Change I
Auto & Auto Ancillaries	4.42	4.42	0%	0	100.00	
Amara Raja Batteries	0.00	0.00	NA	0	0.00	0
Apollo Tyres	0.00	0.00	NA	0	0.00	0
Ashok Leyland	0.18	0.18	0%	0	4.09	-31
Atul Auto	0.00	0.00	NA	0	0.00	0
Bajaj Auto	0.48	0.38	-20%	-10	8.64	-296
Bharat Forge	0.18	0.18	0%	0	4.02	-58
Eicher Motors	0.36	0.36	0%	0	8.21	12
Escorts	0.00	0.02	NA	2	0.40	40
Exide Industries	0.00	0.00	NA	0	0.00	0
Hero Motocorp	0.32	0.32	0%	0	7.28	25
Mahindra & Mahindra	0.87	0.89	2%	2	20.20	528
Maruti Suzuki India	1.02	1.04	2%	2	23.47	0
Motherson Sumi	0.00	0.00	NA	0	0.00	0
Motherson Sumi Wiring India	0.00	0.02	NA	2	0.41	-9
Tata Motors	0.76	0.77	2%	1	17.50	-92
Tata Motors DVR*	0.10	0.11	10%	1	2.50	-16
TVS Motor	0.14	0.14	0%	0	3.27	-40
Cash Source Fredray Research	0.00	0.00	NA	0	0.0	0

Source: Emkay Research

### Sector portfolio NAV

	Base					Latest
	1-Apr-19	30-Apr-21	29-Oct-21	31-Jan-22	31-Mar-22	29-Apr-22
EAP - Auto & Auto Ancillaries	100.0	114.7	135.7	140.7	126.3	132.7
BSE200 Neutral Weighted Portfolio (ETF)	100.0	115.1	134.8	139.6	125.5	132.3

<sup>\*</sup>Performance measurement base date 1st April 2019


Source: Emkay Research

## Price Performance (%)

	1m	3m	6m	12m
EAP - Auto & Auto Ancillaries	5.0%	-5.7%	-2.2%	15.7%
BSE200 Neutral Weighted Portfolio (ETF)	5.4%	-5.3%	-1.9%	14.9%

Source: Emkay Research

### **NAV** chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 05/05/2022 03:49 PM

<sup>■</sup> High Conviction/Strong Over Weight ■ High Conviction/Strong Under Weight

## **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.	
BUY	Over 15%	
HOLD	Between -5% to 15%	
SELL	Below -5%	

Completed Date: 04 May 2022 20:20:55 (SGT) Dissemination Date: 04 May 2022 20:21:55 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

#### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkavolobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.
- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on the sender. Further, this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

#### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of May 4, 2022
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of May 4, 2022.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the May 4, 2022
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the May 4, 2022

<sup>&</sup>lt;sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>&</sup>lt;sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

# **RESTRICTIONS ON DISTRIBUTION**

KESTRICTIONS ON L	DISTRIBUTION
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom.  In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating
Dubai International Financial Centre	to investments should not rely on this communication.  This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

# Emkay Global Financial Services Ltd.

**CIN -** L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com